Review
. 2008 Jul;17(7 Suppl 7):4-8; discussion 17-8.
Understanding tumor profiling and assessing treatment
Affiliations
- PMID: 19093336
Item in Clipboard
Review
Understanding tumor profiling and assessing treatment
Manag Care.
2008 Jul.
Abstract
Gene expression profiling allows us to look into a tumor cell to see how genetic information is communicated and affects cell behavior. Data gathered during the development of the 70-gene assay (MammaPrint) set the stage for future assay development. Recently, a 21-gene assay (Oncotype DX) was recommended by ASCO and NCCN as a standard of care for newly diagnosed, stage 1 or 2, node-negative, estrogen-receptor-positive breast cancer patients.
Similar articles
-
Quantitative biology: a new paradigm for tumor profiling, prognosis, and treatment.Manag Care. 2008 Jul;17(7 Suppl 7):3; discussion 17-8. Manag Care. 2008. PMID: 19097281 No abstract available.
-
A health plan's integration of molecular diagnostics and the impact on treatment pathways for quality care.Manag Care. 2008 Jul;17(7 Suppl 7):13-6; discussion 17-8. Manag Care. 2008. PMID: 19093337
-
Assessing therapeutically developed assays.Manag Care. 2008 Jul;17(7 Suppl 7):9-12; discussion 17-8. Manag Care. 2008. PMID: 19097282 Review.
-
Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.Adv Anat Pathol. 2009 Jul;16(4):204-15. doi: 10.1097/PAP.0b013e3181a9d4bf. Adv Anat Pathol. 2009. PMID: 19546609 Review.
-
Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?Am J Surg. 2008 Oct;196(4):527-9. doi: 10.1016/j.amjsurg.2008.06.021. Am J Surg. 2008. PMID: 18809056
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical